产品介绍
Product Description
Biochem/physiol Actions
TIR domain-targeting MyD88 homodimerization inhibitor that blocks MyD88 signaling and prevents colitis-associated cancer (CAC) development in vivo.
TJ-M2010-5 (TJ-5) is a TIR domain-targeting MyD88 homodimerization inhibitor (67% inhibition of HEK293 cellular MyD88 interaction at 20 µM) that blocks IRAK4, ERK and p38 phosphorylation induction by LPS stimulation (100 ng/mL for 6h with or without 40 µM TJ-5) in RAW 264.7 cells. TJ-5 (50 mg/kg/d i.p.) significantly reduces AOM/DSS-induced colitis and completely prevents colitis-associated cancer (CAC) development and death (53% mortality of control mice) in mice in vivo.
技术参数
Specifications
| Quality Segment | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear |
| storage temp. | 2-8°C |
| SMILES string | O=C(CCN1CCN(CC1)CC2=CC=CC=C2)NC3=NC(C4=CC=CC=C4)=CS3 |
